PBSC collection on the 1st day of collection showed almost no fall in WBC or PB CD34 counts even after 4 hours of collection. The mean day 1 collection was 9.2 (11.3 SD) x10E6 CD34/kg vs. 10.7 (7.1) x10E6/kg for PF and F mobilization, respectively. PF patients also received a single SC injection of F (10 mcg/kg) on the evening following the first PBSC collection. The second day of collection averaged 8.4x10E6 (7.2) CD34/kg. Myalgias/arthralgias were the o nly reported side effects in 3 patients starting the day before collection. We conclude that PF can successfully mobilize high yields of PBSC following chemotherapy priming using standard apheresis procedures. Future studies will investigate optimal dosing, use of PF alone and also whether F can be omitted after the 1st apheresis.
Background. Chronic GvHD remains a major complication of alternative donor transplants, and it is uncertain how this late complication can best be prevented. Objective. To study the impact of preparative regimens with or without anti-thymocyte globulin (ATG) on chronic graft versus host disease (GvHD) in 160 patients undergoing a marrow transplants from unrelated donors (n=127) or partially mismatched family donors (n=33). Methods. Rabbit ATG (Thymoglobuline, Sangstat) ,7.5-15 mg/kg was given within the conditioning regimen to 102 patients, whereas 58 patients received no ATG. The median age was 34 years for the ATG group and 29 and for the non-ATG group (p=0.002); otherwise the two groups were matched for disease phase , diagnosis, donor age, interval diagnosis transplant, and number of cells infused at the time of transplant. Median follow up for surviving patients is 4.5 years (range 1.5-9). The conditioning regimen was cyclophosphamide (CY) and total body irradiation (TBI) in 95 and CY-Thiotepa in 65 patients, the source of stem cells was bone marrow for all patients. Results. Acute GvHD grade II-IV and grade III-IV was reduced in patients receiving ATG (51% vs 74%, p=0.004 and 14% vs 28%, p=0.03 respectively). In the ATG group there were significantly less patients with chronic GvHD at 6 months (14% vs 30% p=0.03), one year (7% vs 41% p=0.0001) 2 years (16% vs 36%, p=0.02) 4 years (6% vs 39%, p= 0.002) and beyond 4 years (0% in 19 patients at risk vs 30% in 24 patients at risk, p=0.01). In the ATG group there were more patients with a performance status (Karnowski score) greater than 90 at last follow up (93% vs 56% , p=0.01) and more patient off cyclosporin two year post transplant (28% vs 3%, p=0.003). Survival in the ATG/non-ATG groups was comparable for patients receiving TBI (56% vs 59%,p=0.7) and for patient receiving thiotepa (33% vs 18%,p=0.3), as well as transplant mortality and relapse. Conclusions. We conclude that ATG pre-transplant reduces the risk of acute and chronic GvHD, improves quality of life and increases the likelihood to discontinue immunosuppressive therapy. This also suggests that in vivo T cell depletion pretransplant has a major impact on chronic GvHD many years post-transplant.
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Long-term follow-up after stem cell transplantation for chronic myeloid leukemia in 1st chronic phase M. Yeshurun, P. Guardiola, A. Devergie, L. Ades, P. Ribaud, H. Esperou, E. Gluckman, G. Socié (Paris, F) While allogeneic Stem Cell Transplantation (SCT) for Chronic Myeloid Leukemia (CML) 1st Chronic Phase (CP), has been one of the main indication of transplantation before the STI era, surprisingly few data are available on the long-term outcomes on such transplant and on the rates and risk factors (RF) of late complications. From 1982 to 1998, 103 patients (pts) underwent non-manipulated SCT for CML 1st CP from a sibling donor in our center (median follow-up 6.5 years, range, 1.7-18.1 years). Median age at transplant was 36 years (range, 8-56 years) . 43 pts have been previously treated with IFN. Sokal's score at diagnosis was low in 66 pts, intermediate in 15 pts, and high in 14 pts (missing, 8) . BuCY was used in 63% and Cy-TBI in 37% of the pts for conditioning. All pts received CsA for GvHD prophylaxis (CsA+MTX in 78 pts). The 7-year estimated survival was 57% (95%CI: 48-67%). The 7-year relapse (cytogenetic or hematological) and TRM incidences were 5% and 37%. In multivariate analysis, pre-transplant-RF associated with decreased survival and increased TRM were older age, GvHD prophylaxis with CsA alone, and absence of hematological remission before SCT. Post-transplant-RF associated with survival and TRM included steroid-resistant GvHD and fungal infections. 7-year chronic GvHD incidence rate was 71% and was associated with splenectomy, PBSC, acute GvHD, and CMV infection, in multivariate analysis. 7-year estimated incidences of cataract, osteonecrosis, thyroid dysfunction, osteoporosis bacterial infections and depression were 46%, 57%, 22%, 15%, 11%, 46%, and 32%. 5 patients developed a solid tumor. RF associated (multivariate analyses) with cataract, depression and bone diseases was extensive chronic GvHD.
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Single center evaluation of thyroid function abnormalities following hematopoetic stem cell transplant S. Kulkarni, R. Powles, B. Sirohi, J. Brennan, J. Treleaven, R. Saso, S. Sankpal, J. Metha, S. Singhal, M. Ortin, C. Pinkerton, C. Horton (Sutton, UK) The prospectively maintained database at this hospital identified 1560 patients who received allogeneic (n=1050,M: 616, F:434, median age:27, range:0-56 yr.), autologous (n=486, M:293, F:193; median age:31, range:1-74) or syngeneic transplant (n=24, M:14, F:10; median age:33, range:2-65 yr.). These patients were evaluated to identify the incidence and risk factors for the development of thyroid gland hypo function. All patients who had biochemical evidence of hypothyroidism were included in the analysis. Transplants w ere done for acute leukaemia (n=1179), chronic leukaemia (n=184) or other haematological disorders (n=197). Conditioning therapy was with TBI in 1187 patients and with chemotherapy in 373 patients. The donor was HLA identical sibling in 877 patients, matched unrelated donor in 121 and mismatched family member in 52 cases. For allograft patients GVHP consisted of CyA in 522 cases CyA+Mtx in 483 cases and other measures in 45 cases. Disease stage was good risk in 855 patients and poor risk in 705 cases. 62 patients developed thyroid dysfunction (27 allograft, 35 autograft). The risk of thyroid dysfunction was 10% at 10 yr. Thyroid dysfunction developed at a median of 4.1 yr. (range:0.3-12 yr.). In univariate analysis, thyroid dysfunction was significantly higher for patients younger than 16yr. age (20% vs. 5%, p<0.0001), autograft (13% vs. 3%, p<0.0001), TBI conditioning (13% vs. 5%, p=0.035), TBI dose >9,5 Gy. (15% vs. 4%, p=0.0006), acute GVHD (5% vs. 2%, p=0.03). There was no effect of patient sex, source of stem cells, donor sex, and patient/donor blood group match. In multivariate analysis, age <16 yr. (RR: 4.1, 95% CI: 2.44-6.8, p<0.0001), TBI conditioning (RR: 2.85, 95% CI: 1.14-7.2, p=0.03) and autograft (RR: 3.6, 95% CI: 2.15-5.94, p<0.0001) were independently associated with increased risk of thyroid dysfunction. The overall survival for the autograft patients was 45% at 5yr. and for allograft patients the OS was 40%. This single-centre analysis shows that there is a significant risk of thyroid dysfunction following haematopoetic stem cell transplant. The risk is more in young pre-pubertal patients and seems to increase even beyond 10 yr. It is imperative that long-term survivors of allo or autograft should be monitored for the delayed complications, every effort made to detect these complications early on, and appropriate therapy instituted in this group of patients.
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Long-term follow-up of hepatitis C virus -infected allogeneic SCT recipients: high incidence of cirrhosis and cancers R. Peffault de Latour, V. Lévy, T. Asselah, L. Adès, R. Traineau, A. Devergie, P. Ribaud, H. Esperou, D. Valla, E. Gluckman, G. Socié (Paris, F) Long-term outcome of patients (pts) infected with Hepatitis C virus (HCV) is poorly documented. We studied 96 Pts who had been infected by the HCV during the transplant period (Transfusion) from 1974 to 1995. The median follow up of the cohort is 14 years (Yrs). There were 53 men and 43 women (median age at transplant: 19 yrs). Underlying diagnosis included: 50 hematological malignancies, 40 aplastic anemia and 6 others diagnoses. Conditioning regimen included TBI in 79 pts. GvHD prophylaxis consisted in cyclosporine +/-methotrexate in 78 pts. All but 14 pts were grafted from an HLA-identical sibling donor. In the early period post-SCT, 4 pts developed VOD, 29 pts acute GvHD (Grade 2 or more), and 55 chronic GvHD. Fifteen pts developed an HCV-related disorders (HCV-RD) such as glomerulonephritis or cryoglobulinemia. Cirrhosis (as defined by pathological findings) was diagnosed in 15 pts. The cumulative incidence of cirrhosis (with death from others causes considered as a competing event) was 2%, 11% and 24% at 10, 15 and 20 yrs, respectively. Analysis of factors associated with cirrhosis was performed using Grays' test to take into account competing events. In univariate analysis, the following factors were significantly associated with cirrhosis: male gender (p=.03), VOD of the liver (p<.001), active chronic hepatitis (p=.02) and HCV-RD (p<.001). By multivariate analysis (Fine and Gray), 3 factors remained significant: active chronic hepatitis (hazard ratio (HR)= 1.56, p=.006) and HCV-RD (HR=2.33, p<.001) and VOD (HR=2.15, p=.04). Fibrosis progression, as defined by the ratio between fibrosis stage in METAVIR units and duration of infection (Poynard et al, Lancet 1997) , was compared with an HCV non-SCT population (n=297 pts). The median estimated duration of progression to cirrhosis was 18 years in our population as compared to 40 years in non-SCT Pts. Fourteen pts developed cancers (including 3 hepatocellular carinoma (HCC), leading to 4%, 8% and 16% cumulative incidences of cancers at 10, 15 and 20 yrs, respectively (that of HCC being 2% and 5% at 15 and 20 yrs respectively). Only chronic GvHD was associated with cancer risk (p=.02). Clinical and histological monitoring is recommended on the long term follow up in HCVinfected SCT recipients to identify pts developing rapid liver fibrosis.
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A retrospective comparison of oral versus intravenous administration of busulfan M. Arat, P. Topcuoglu, E.A. Soydan, G. Gürman, M. Ozcan, O. Arslan, H. Koc, O. Ilhan, N. Konuk, A. Uysal, H. Akan, M. Beksac (Ankara, TR) Busulfan can be administered intravenously (IVBU) or by oral route (POBU). Due to GI absorption variations POBU presents marked interpatient and interdose deviations. Intravenous formulation (Busulfex) has been shown to be both efficient and safe in clinical Phase I/II trials. Recently we have demonstrated less GI toxicity and TPN use with IVBU (EBMT2002). In this report we extended our matched pair analysis to a population matched for age, stem cell source, risk factors, diagnosis and follow-up duration. POBU and IVBU groups received conventional doses as reported before. The IVBU group had a median age of 26 (14-48) years, diagnosed as AML/CML/MDS/ALL= 13/7/2/1, M/F ratio=17/6 and stem cell source of (peripheral blood/bone marrow) 17/6. Whereas the POBU group had a median age of 31 (17-41), diagnosis of AML/CML/MDS/ALL =12/9/1/1 and the similar ratio for stem cell source. Transplant related complications and outcome are detailed on the table. We observed fewer incidences of nausea/vomiting and diarrhea in IVBU group than in POBU group (p<0.05) as before. In addition, IVBU patients required TPN less (p=0.03). The frequencies of hemorrhagic cystitis or VOD were not different between two groups. Estimated two year overall survival for IVBU and POBU were 86.7% vs 72.3%, respectively. Log-rank analysis of the overall survival and disease free survival curves (Kaplan Meier) of IVBU and POBU patients revealed no significant difference for overall survival 892±60 vs 735±68 days and for disease free survival 755±74 vs 703±70 days, respectively. IVBU is an easy to use prescription with less and acceptable toxicity in regard to POBU. In our p revious matched pair analysis the cost evaluation revealed similar expenses in both arms which is a result of compensation of IVBU costs with the TPN costs. 2002. Lansky and Karnofsky scores (LK-Scores) as well as GvHD and BMI (body mass index) were evaluated prospectively just prior to conditioning and following the transplant at day 100, 1 y and at latest five yrs post transplant. A total of 120 patients met the inclusion criterias of these 56 patients (79% leukemia or MDS) survived long term but 4 pts was lost to follow-up. Donors consisted of HLA-id sib 54%, other fam.donors 15% and matched unrelated 31%. Results: Median LK-score were: 93% (range: 100-50%) before SCT, 88% (range:100-30) day 100 (before vs. d100 p=0,029), 94% (range:100-50) at 1y (d100vs.1y:p<0,001) and 97% (range:100-80) +5yrs (1yvs.+5yrs p=0,006) after SCT. Median BMI (normal range 20-25) were: 21,00 (range: 13-33) before SCT, 19, ) day 100 (before vs. d100 p=0,248), 21,00 (range:13-31) at 1y(d100vs.1y:p=0,566) and 22,00(range:15-30) +5yrs (1yvs.+5yrs p<0,001) after SCT. Precentage of patients with a BMI under 20: before SCT: 40,4%, d100:50,0%, 1y:43,8%, +5yrs:28%. Patients transplanted with alternative donors experienced significant decreased LK-Scores: d100 (p<0,001), 1y (p=0,022) and +5yrs (p=0,003) compared to patients transplanted with HLA-id donors. Patients with Acute GvHD at d100 had a significantly decreased BMI (p=0,03). Patients with Chronic GvHD at 1y and +5yrs had significantly decreased LK-Scores (p=0,046 andp=0,003). Conclusion: Acute GvHD had an impact on BMI. Chronic GvHD had a major impact on LK-Scores. The patients with a poor BMI before, d100 1y post improved their BMI after 1y post SCT, but still 28% has a BMI below 20. However, the majority of long term surviving young patients has a very good performance five or more years after allo SCT. Compared to pre-transplant 91% had an unchanged or increased LK-Score.
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Effect of growth hormone therapy in children and adolescents with growth hormone deficiency after stem cell transplantation C.P. Schwarze, R. Dopfer, G. Binder, H.A. Wollmann, H. ScheelWalter, J. Greil, M.B. Ranke, D. Niethammer (Tuebingen, D) Objective: Effect of GH therapy in patients after stem cell transplantation (SCT) with growth hormone deficiency (GHD) and neurosecretory dysfunction (NSD). Methods: 8 patients (2f/6m) were treated with SCT for cALL (1;2), JCMML (3), MDS (4), SAA (5), NB (6), MB (7) and PNET (8). Patients were followed prospectively up to 0,½,1,2,3,4 and 5 yrs. Height (HT), weight, body proportions and pubertal status were recorded. IGF-I, IGFBP-3, TSH, fT4, LH, FSH, E2, T and for the GH-axis the GH peak in an arginine (AST)-/insulin (ITT) test and the GH secretion were measured. Results: SCT was performed at 7.0 yrs (1.0 to 11.8) (median,range).
Treatment before SCT consisted of chemotherapy (CT)(8x) combined with cranial irradiation (CI)(1x), TBI(1x) and local irradiation (LI)(1x). 4 patients (2,3,7,8) had a previous SCT. Conditioning for SCT (6x allo/2x auto) was CT(3x), CT/TBI(3x), CT/CI/TBI(1x) and CT/LI(1x). A Hypothyroidism in 6 patients (1-5;8) was treated. HT was reduced before SCT at -1.6 SDS (-1.1 to -3.3), vs. target HT at 0.0 SDS (-1.35 to +1.06 (n=8)), p<0.02. Growth failure 2.3 yrs (1.8 to 5.1) after SCT resulted in a HT reduction at -2.6 SDS (-0.6 to -4.3) with a loss of -1.0 SDS (-0.3 to -1.2). IGF-I was very low in all patients at -3.5 SDS (-1.9 to -5.2), IGFBP-3 was very low in 6 patients (3-8) at -3.2 SDS (-2.5 to -5.5) and normal in 2 patients (1,2) at -1.3 and -0.9 SDS. ASTs showed GH peaks of 4.8 mg/dl (1.2 to 14.1) (n=8), ITTs of 4.5/5.8/7.2 mg/dl and GH secretion of 1.6/1.7/2.5 mg/dl in patients with GHD (cut off at 8.0 mg/dl). In the patient with NSD (8), GH peaks were 16.3 and 15.2 mg/dl (2 ASTs). IGF-I and IGFBP-3 increased in the generation test (0.1 IU/kgday) from -3.4 to +0.3 and -5.5 to -1.3 SDS. GH doses used were 0.6 IU/kgweek (0.5 to 0.9). HT velocity before GH therapy was reduced at -2.7 SDS (-1.1 to -3.2), 2.1 to 5.2cm/yr, and increased during GH therapy to +2.6 SDS ( -1.2 to +6.3), 4.6 to 8.4 cm/yr. IGF-I and IGFBP-3 normalised after GH therapy at +0.6 SDS (-0.8 to +1.5) and -0.4 SDS (-1.9 to +0.7). At the last visit 3.2 yrs (0.4 to 4.5) after GH therapy HT-SDS had increased in 5 patients (1;4;5;7;8) by +0.5 SDS (+0.3 to +1.1), was unchanged in 1 patient (6) 0.0 SDS, and had decreased in 2 patients (2,3) by -0.6 and -0.7 SDS due to a hypergonadotropic hypogonadism and intensive prednisolone/ dexamethasone therapy. Conclusions: GHD may be the cause of progressive growth failure after SCT in patients receiving CT/TBI but also CT only. GH therapy normalises growth and induces catch-up growth.
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Quality of life and adjustment of pediatric patients receiving allogeneic stem cell transplantation -interim results of a multicenter longitudinal study R. Felder-Puig, A. di Gallo, M. Waldenmair, P. Norden, A. Winter, H. Gadner, R. Topf (Vienna, A; Basel, CH; Innsbruck, Graz, A) Objectives: This presentation describes first results of an ongoing effort to assess the quality of life (QoL) and adjustment of pediatric patients receiving allogeneic stem cell transplantation (SCT). The study design is based on a prospective approach and involves 4 institutions where SCT is performed in pediatric patients. Methods: Eligible subjects include all German-speaking patients aged >= 3 years who receive SCT between January 2000 and December 2003. The patients are assessed seven times: 4-6 weeks (T1) and 7 days (T2) prior to SCT, and 10 (T3), 28 (T4), 100 (T5), 180 (T6) and 360 (T7) days post SCT. For the measurement of various domains of QOL, standardized instruments (HUI -Health Utilities Index and PedsQL™ -Pediatric Quality of Life Inventory™) have to be completed by patients, parents, and physicians. Further information gathered include treatment-related coping and compliance of child and parent, the child's and the family's history, and detailed medical information at 4 of the 7 defined time points. Results: So far, we have collected data about 40 SCT recipients aged 3-17 years at the time of the transplantation. Scores of global QoL show a large variability, with some patients doing quite well throughout the course of the treatment, and others who tremendously suffer from an unfavourable evolution. Generally, global QoL is worst at T3 and T5, but is better at T7 than at baseline (T1). T3 is the most critical time point with regard to emotion, pain, and nausea. Worries about the side-effects of treatment and fear of a relapse remain relatively stable between T1 and T5, and slightly increase after discharge from the transplantation unit (T6). Physical functioning of patients has been found to be significantly reduced at baseline, is even worse at T6 but improves until T7. Discrepancies between physicians' and parents' or patients' assessments are most evident at T3. At all other measurement points, correlations are in the medium range without any clear pattern as to whether physicians tend to over-or underestimate problems. Further, we will present individual cases that show the relative importance of transplant type, treatment-related complications and coping of patient and/or mother on specific QoL domains at the various stages of treatment. Conclusion: Altogether, the instruments' scores reflect very well the psychological and physical stressors patients and families are confronted with during SCT therapy.
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Rearrangements unrelated to the original neoplastic clone are associated to late but not early repositivization of the Bcl-2/IgH PCR in autografted follicular lymphoma patients M. Ladetto, M. Astolfi, I. Ricca, M. Compagno, B. Mantoan, S. Vallet, D. Drandi, M. Boccadoro, P. Corradini, C. Tarella (Turin, Milan, I) Molecular repositivization of the Bcl-2/IgH nested PCR assay is an uncommon but well-defined event among follicular lymphoma (FL) patients achieving molecular remission (MR) after autografting. This finding is regarded as a clear evidence of active disease and associated with a high risk of clinical relapse. Although we have recently observed on a large sample of
